Glasgow Asthma and Allergy Study (GLAAS)
In the past, doctors separated people with asthma into two groups, those with "allergic asthma" (about 2/3rds of people) and those with "non-allergic asthma". These labels are not much used now as the treatments for all people with asthma don't depend on this classification. However, new treatments for asthma may become available and the classification may again become important. It could be useful for clinicians to know how to identify which patients are likely to benefit from particular treatments.
Additionally, some new blood tests are becoming available and some of these might help to categorise the type of asthma people have. What the study hopes to do is to identify patient features which make a diagnosis of "allergic asthma" more likely and to see which new blood tests are most likely to be helpful in confirming this diagnosis.
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Cross Sectional Study to Evaluate and Associate Clinical and Laboratory Features of People With Allergic and Non-allergic Asthma|
- Serum periostin level [ Time Frame: 1 day ] [ Designated as safety issue: No ]This is a cross sectional study. Participants will be assessed and tests conducted at a single visit
- skin prick test [ Time Frame: 1 day ] [ Designated as safety issue: No ]
- Serum total IgE [ Time Frame: 1 day ] [ Designated as safety issue: No ]
- Blood eosinophil count [ Time Frame: 1 day ] [ Designated as safety issue: No ]
- Blood neutrophil count [ Time Frame: 1 day ] [ Designated as safety issue: No ]
- Blood CD4 cells that are positive for CRTh2 [ Time Frame: 1 day ] [ Designated as safety issue: No ]
- Blood eosinophils expressing CRTh2 [ Time Frame: 1 day ] [ Designated as safety issue: No ]
- Spirometry [ Time Frame: 1 day ] [ Designated as safety issue: No ]
|Study Start Date:||June 2012|
|Study Completion Date:||October 2013|
|Primary Completion Date:||October 2013 (Final data collection date for primary outcome measure)|
General asthma population
People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01618318
|Dartford, Kent, United Kingdom, DA1 5GA|
|Principal Investigator:||John A Haughney, MB ChB||NSHI Ltd|